Company intelligence / Profile preview
Centrexion Therapeutics
United Statescentrexion.com ↗
- Ownership
- Private
- Employees
- ~24
- Development stage
- Other
01
Overview
Centrexion’s lead asset CNTX‑4975 has demonstrated significant and durable relief from moderate-to-severe knee osteoarthritis pain by the second day post-injection. The VICTORY Phase III program includes three pivotal trials evaluating efficacy and safety. Other pipeline assets are advancing through early to mid-stage clinical development targeting additional chronic/inflammatory/neuropathic indications with non-opioid mechanisms.
- Therapeutic areas
- DermatologyImmunologyNeurologyRheumatology
- Modalities
- Small molecules (e.g., SSTR4 agonist, CCR2 antagonist)Topical gel (lidocaine formulation)Cannabinoid agonistsTRPV1 agonist (capsaicin)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
Eli Lilly & Co. – licensing deal for CNTX–0290
Beyond the preview
Go deeper on Centrexion Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Centrexion Therapeutics.